Cox et al1  reported that interleukin-3 (IL-3), IL-7, and stem-cell factor (SCF) promote the expansion of B-lineage acute lymphoblastic leukemia (ALL) cells. We cultured 9 cases of B-lineage ALL (8 CD10+ CD19+, 1 CD10-CD19+) with IL-3, IL-7, and SCF as described by Cox et al. Cells became apoptotic, and viable leukemic-cell recovery after 2 weeks of culture was less than 0.01% to 3.6% (median 0.2%) of the input cell number. Cox et al1  also reported the complete failure of ALL cells to survive on mesenchymal cells in their study, even in the presence of the factors that they found to be supportive. In 5 B-lineage ALL cases, we compared the cultures with growth factors described by Cox et al1  to cultures with mesenchymal cells (without growth factors or serum). Median leukemia-cell recovery after 1 week of culture with growth factors and no mesenchymal cells was only 5% (range 0.01%-45%) of input cells; after culture on mesenchymal cells, it was 129% (range 55%-176%). After 3 weeks, cell recovery was 1% in all 5 cultures with growth factors. By contrast, viable leukemic cells persisted in 4 of the 5 cases cultured on mesenchymal cells, representing 17%, 25%, 108%, and 147% of the cells originally seeded. These results contrast with those reported by Cox et al,1  but are in agreement with those of previous studies indicating that mesenchymal cells are essential to support ALL cell viability in vitro,2-8  whereas growth factors may induce short-term proliferation in a few cases of ALL but do not support viability and expansion of ALL cells.4,9 -11 

A second issue raised by Cox et al1  is the immunophenotype of the putative ALL stem cells. We think that there are technical issues that must be addressed before concluding that the only cells that can engraft immunodeficent mice lack CD19 (or CD10) expression. Cox et al1  used an anti–CD19 antibody conjugated to fluorescein isothiocyanate, which, as shown in Figure 1 of their paper, yields a relatively weak staining resulting in relatively high percentages of CD34+CD19- cells. We reviewed expression of CD34 and of CD19 (detected with allophycocyanin- or phycoerythrin-conjugated antibodies) in 50 B-lineage ALL samples: with few exceptions, CD34+CD19- cells were either undetectable or formed a separate cluster, apparently unrelated to the bulk leukemia-cell population. Hotfilder et al12  sorted TEL-AML1+ leukemia cells according to their CD19 expression in 8 cases and found that CD19- cells either lacked TEL-AML1 transcripts (n = 3) or contained an estimated percentage of TEL-AML1+ cells ranging from 0.1% to 6% (n = 5). The latter percentages correlated with those of contaminating CD19+ cells in control sorts, suggesting that the low TEL-AML1 signals observed in the sorted CD34+CD19- cells could have been derived from contaminating CD19+ cells. These authors did not perform ALL cell-growth assays with CD34+CD19- cells, but observed that they gave rise to myeloid, monocytic, and erythroid colonies, indicating that most, if not all, were normal hematopoietic cells. In fact, Anthony et al13  recently reported that expression of CD19 was useful to distinguish leukemic CD34+CD38- cells from normal CD34+CD38- primitive hematopoietic cells in B-lineage ALL samples. It may be that CD19 expression is weaker on ALL cells with the least stringent growth requirements, or that CD19 on these cells modulates more actively after antibody binding, but it is premature to conclude that ALL stem cells lack CD19. This issue needs careful attention because CD19 is a candidate target for immunotherapies of B-cell malignancies, including B-lineage ALL.

1
Cox CV, Evely RS, Oakhill A, Pamphilon DH, Goulden NJ, Blair A. Characterization of acute lymphoblastic leukemia progenitor cells.
Blood
.
2004
;
104
:
2919
-2825.
2
Gluck U, Zipori D, Wetzler M, et al. Long-term proliferation of human leukemia cells induced by mouse stroma.
Exp Hematol.
1989
;
17
:
398
-404.
3
Novotny JR, Duehrsen U, Welch K, Layton JE, Cebon JS, Boyd AW. Cloned stromal cell lines derived from human Whitlock/Witte-type long-term bone marrow cultures.
Exp Hematol.
1990
;
18
:
775
-784.
4
Manabe A, Coustan-Smith E, Behm FG, Raimondi SC, Campana D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia.
Blood
.
1992
;
79
:
2370
-2377.
5
Nishigaki H, Ito C, Manabe A, et al. Prevalence and growth characteristics of malignant stem cells in B-lineage acute lymphoblastic leukemia.
Blood
.
1997
;
89
:
3735
-3744.
6
Bradstock K, Bianchi A, Makrynikola V, Filshie R, Gottlieb D. Long-term survival and proliferation of precursor-B acute lymphoblastic leukemia cells on human bone marrow stroma.
Leukemia
.
1996
;
10
:
813
-820.
7
Nishii K, Katayama N, Miwa H, et al. Survival of human leukaemic B-cell precursors is supported by stromal cells and cytokines: association with the expression of bcl-2 protein.
Br J Haematol.
1999
;
105
:
701
-710.
8
Ito C, Kumagai M, Manabe A, et al. Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis.
Blood
.
1999
;
93
:
315
-320.
9
Makrynikola V, Kabral A, Bradstock KF. Effects of recombinant human cytokines on precursor-B acute lymphoblastic leukemia cells.
Exp Hematol.
1991
;
19
:
674
-679.
10
Eder M, Ottmann OG, Hansen-Hagge TE, et al. In vitro culture of common acute lymphoblastic leukemia blasts: effects of interleukin-3, interleukin-7, and accessory cells.
Blood
.
1992
;
79
:
3274
-3284.
11
Mirro JJ, Hurwitz CA, Behm FG, et al. Effects of recombinant human hematopoietic growth factors on leukemic blasts from children with acute myeloblastic or lymphoblastic leukemia.
Leukemia
.
1993
;
7
:
1026
-1033.
12
Hotfilder M, Rottgers S, Rosemann A, Jurgens H, Harbott J, Vormoor J. Immature CD34+CD19- progenitor/stem cells in TEL/AML1-positive acute lymphoblastic leukemia are genetically and functionally normal.
Blood
.
2002
;
100
:
640
-646.
13
Anthony J, George A, Senadheera S, et al. Comparison of gene expression by normal and leukemic progenitor cells in childhood B cell precursor ALL: are there ALL stem cells?
Blood
.
2004
;
104
:
564
a.
Sign in via your Institution